Histone Deacetylase Inhibitors: Potent Anti-Leukemic Agents

Author(s): Jiang Bian, Lihui Zhang, Yantao Han, Chunbo Wang, Lei Zhang

Journal Name: Current Medicinal Chemistry

Volume 22 , Issue 17 , 2015

Become EABM
Become Reviewer
Call for Editor


Leukemia is a life threatening disease that has become increasingly common. Many categories of anti-leukemic agents have been developed by probing into the nature of leukemia. Nevertheless, the needs for potent molecules with few side effects are still not satisfied in the current anti-leukemic therapy. Targeted therapy has been developed for the advantage of relatively high efficiency and safety in the anticancer chemotherapy. Among the targeted antitumor therapies, inhibition of histone deacetylases has been intensively studied. Three histone deacetylase inhibitors (HDACIs) have been approved by US Food and Drug administration (FDA) for the treatment of cancer. Interestingly, a number of HDACIs selectively exhibited inhibitory effects on leukemic cell lines in the preclinical researches. Herein, the anti-leukemic HDACIs were reviewed to gain insight into HDACIs’ potential as anti-leukemic agents.

Keywords: Anti-leukemia, clinical trial, HDACs, inhibitor, preclinical study, selectivity.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [2065 - 2074]
Pages: 10
DOI: 10.2174/0929867322666150416094720
Price: $65

Article Metrics

PDF: 35